|
1
|
Zhu KP, Zhang CL, Ma XL, Hu JP, Cai T and
Zhang L: Analyzing the interactions of mRNAs and ncRNAs to predict
competing endogenous RNA networks in osteosarcoma chemo-resistance.
Mol Ther. 27:518–553. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao X, Wu Q, Gong X, Liu J and Ma Y:
Osteosarcoma: A review of current and future therapeutic
approaches. Biomed Eng Online. 20:242021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rothzerg E, Pfaff AL and Koks S:
Innovative approaches for treatment of osteosarcoma. Exp Biol Med.
247:310–316. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eaton BR, Schwarz R, Vatner R, Yeh B,
Claude L, Indelicato DJ and Laack N: Osteosarcoma. Pediatr Blood
Cancer. 68:e283522021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rothzerg E, Ingley E, Mullin B, Xue W,
Wood D and Xu J: The hippo in the room: targeting the hippo
signalling pathway for osteosarcoma therapies. J Cell physiol.
236:1606–1615. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gamie Z, Kapriniotis K, Papanikolaou D,
Haagensen E, Da Conceicao Ribeiro R, Dalgarno K,
Krippner-Heidenreich A, Gerrand C, Tsiridis E and Rankin KS:
TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma
treatment: Pre-clinical and clinical data. Cancer Lett. 409:66–80.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang X, Ma Z, Zhu G, Lu Y and Yang J: New
perspective into mesenchymal stem cells: Molecular mechanisms
regulating osteosarcoma. J Bone Oncol. 29:1003722021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akiyama T, Dass CR and Choong PF: Novel
therapeutic strategy for osteosarcoma targeting osteoclast
differentiation, bone-resorbing activity, and apoptosis pathway.
Mol Cancer Ther. 7:3461–3469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Broadhead ML, Clark JC, Dass CR, Choong PF
and Myers DE: Therapeutic targeting of osteoclast function and
pathways. Expert Opin Ther Tar. 15:169–181. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rojo R, Raper A, Ozdemir DD, Lefevre L,
Grabert K, Wollscheid-Lengeling E, Bradford B, Caruso M, Gazova I,
Sánchez A, et al: Deletion of a Csf1r enhancer selectively impacts
CSF1R expression and development of tissue macrophage populations.
Nat Commun. 10:32152019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sehgal A, Donaldson DS, Pridans C, Sauter
KA, Hume DA and Mabbott NA: The role of CSF1R-dependent macrophages
in control of the intestinal stem-cell niche. Nat Commun.
9:12722018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jones CV and Ricardo SD: MacrophagesCSF-1:
Implications for development and beyond. Organogenesis. 9:249–260.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sehgal A, Irvine KM and Hume DA: Functions
of macrophage colony-stimulating factor (CSF1) in development,
homeostasis, and tissue repair. Semin Immunol. 54:1015092021.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Emoto T, Lu J, Sivasubramaniyam T, Maan H,
Khan AB, Abow AA, Schroer SA, Hyduk SJ, Althagafi MG, McKee TD, et
al: Colony stimulating factor-1 producing endothelial cells and
mesenchymal stromal cells maintain monocytes within a perivascular
bone marrow niche. Immunity. 55:862–878. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wen J, Wang S, Guo R and Liu D: CSF1R
inhibitors are emerging immunotherapeutic drugs for cancer
treatment. Eur J Med Chem. 245:1148842023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cannarile MA, Weisser M, Jacob W, Jegg AM,
Ries CH and Rüttinger D: Colony-stimulating factor 1 receptor
(CSF1R) inhibitors in cancer therapy. J Immunother Cancer.
5:532017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tie Y, Tang F, Wei YQ and Wei XW:
Immunosuppressive cells in cancer: Mechanisms and potential
therapeutic targets. J Hematol Oncol. 15:612022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tap WD, Wainberg ZA, Anthony SP, Ibrahim
PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro
GI, et al: Structure-guided blockade of CSF1R kinase in
tenosynovial giant-cell tumor. N Engl J Med. 373:428–437. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mun SH, Park PSU and Park-Min KH: The
M-CSF receptor in osteoclasts and beyond. Exp Mol Med.
52:1239–1254. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Smeester BA, Slipek NJ, Pomeroy EJ,
Laoharawee K, Osum SH, Larsson AT, Williams KB, Stratton N,
Yamamoto K, Peterson JJ, et al: PLX3397 treatment inhibits
constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor
growth, and metastatic burden in osteosarcoma. Bone.
136:1153532020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thongchot S, Duangkaew S, Yotchai W,
Maungsomboon S, Phimolsarnti R, Asavamongkolkul A, Thuwajit P,
Thuwajit C and Chandhanayingyong C: Novel CSF1R-positive
tenosynovial giant cell tumor cell lines and their pexidartinib
(PLX3397) and sotuletinib (BLZ945)-induced apoptosis. Hum Cell.
36:456–467. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs over the nearly four decades from 01/1981
to 09/2019. J Nat Prod. 83:770–803. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Palmerini E, Sapienza MR, Pileri SA, Frega
G, Righi A, Parafioriti A, Franchi A, Agostinelli C, Righi S,
Meazza C, et al: Tumor immune microenvironment-associated
prognostic and mifamurtide-response gene signatures for localized
osteosarcoma: A correlative study of the ISG/OS-2 Trial. Clin
Cancer Res. 31:3932–3943. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Q: Identification of biomarkers for
metastatic osteosarcoma based on DNA microarray data. Neoplasma.
62:365–371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li R, Yan L, Jiu J, Liu H, Li D, Li X,
Zhang J, Li S, Fan Z, Lv Z, et al: PSME2 offers value as a
biomarker of M1 macrophage infiltration in pan-cancer and inhibits
osteosarcoma malignant phenotypes. Int J Biol Sci. 20:1452–1470.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Niu X, Tian W, Ke Y, Li Y and Zhang X:
CAFs exosomal miR-21-5p suppresses ferroptosis and promotes
proliferation and migration in osteosarcoma. Cancer Cell Int.
25:3082025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yao Z, Getting SJ and Locke IC: Regulation
of TNF-induced osteoclast differentiation. Cells. 11:1322021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Günther T, Poli C, Müller JM,
Catala-Lehnen P, Schinke T, Yin N, Vomstein S, Amling M and Schüle
R: Fhl2 deficiency results in osteopenia due to decreased activity
of osteoblasts. EMBO J. 24:3049–3056. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang C, Tao H, Zhang H, Xia Y, Bai J, Ge
G, Li W, Zhang W, Xiao L, Xu Y, et al: TET2 regulates
osteoclastogenesis by modulating autophagy in OVX-induced bone
loss. Autophagy. 18:2817–2829. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matsuo K, Owens JM, Tonko M, Elliott C,
Chambers TJ and Wagner EF: Fosl1 is a transcriptional target of
c-Fos during osteoclast differentiation. Nat Genet. 24:184–187.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu K, Jia Y, Li Y, Liang J, Liu S, Zhu Y,
Liu X, Li X and Liu Z: Comprehensive analysis of an ATF/CREB
family-based signature with regard to prognosis and immune feature
in adrenocortical carcinoma: A cohort study. Int J Surg.
111:8169–8182. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jo S, Kim T, Iyer VG and Im W: CHARMM-GUI:
A web-based graphical user interface for CHARMM. J Comput Chem.
29:1859–1865. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dou F, Lu D and Gao J: Vimseltinib: A
novel colony stimulating factor 1 receptor (CSF1R) inhibitor
approved for treatment of tenosynovial giant cell tumors (TGCTs).
Intractable Rare Dis Res. 14:143–144. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gelderblom H, Razak AA, Taylor MH, Bauer
TM, Wilky B, Martin-Broto J, Gonzalez AF, Rutkowski P, Szostakowski
B, Alcindor T, et al: csf1r inhibition in patients with advanced
solid tumors or tenosynovial giant cell tumor: A Phase I study of
vimseltinib. Clin Cancer Res. 30:3996–4004. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Y, Dan Y, Yang D, Hu Y, Zhang L,
Zhang C, Zhu H, Cui Z, Li M and Liu Y: The genus anemarrhena bunge:
A review on ethnopharmacology, phytochemistry and pharmacology. J
Ethnopharmacol. 153:42–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bao W, Pan H, Lu M, Ni Y, Zhang R and Gong
X: The apoptotic effect of sarsasapogenin from Anemarrhena
asphodeloides on HepG2 human hepatoma cells. Cell Biol Int.
31:887–892. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang W, Wang D, Wang Z, Yao G, Li X, Gao
P, Li L, Zhang Y, Wang S and Song S: Synthesis of new
sarsasapogenin derivatives with cytotoxicity and apoptosis-inducing
activities in human breast cancer MCF-7 cells. Eur J Med Chem.
127:62–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mandlik DS, Mandlik SK and Patel S:
Protective effect of sarsasapogenin in TNBS induced ulcerative
colitis in rats associated with downregulation of pro-inflammatory
mediators and oxidative stress. Immunopharmacol Immunotoxicol.
43:571–583. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen R, Ying C, Zou Y, Lin C, Fu Q, Xiang
Z, Bao J and Chen W: Sarsasapogenin inhibits YAP1-dependent
chondrocyte ferroptosis to alleviate osteoarthritis. Biomed
Pharmacother. 168:1157722023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dai Y, Liu P, Wen W, Li P, Yang C, Wang P
and Xu S: Sarsasapogenin, a principal active component absorbed
into blood of total saponins of anemarrhena, attenuates
proliferation and invasion in rheumatoid arthritis fibroblast-like
synoviocytes through downregulating PKM2 inhibited pathological
glycolysis. Phytother Res. 37:1951–1967. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang F, Zhang F, Lin B, Xiao W, Wang X and
Wang N: Sarsasapogenin stimulates angiogenesis and osteogenesis
coupling to treat estrogen deficiency-induced osteoporosis by
activating the GPX4/SLIT3/ROBO1 axis. Phytomedicine.
136:1562972025. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pan P, Zhang Z, Xu Y, Li F, Yang Q and
Liang B: Sarsasapogenin inhibits HCT116 and caco-2 cell malignancy
and tumor growth in a xenograft mouse model of colorectal cancer by
inactivating MAPK signaling. J Biochem Mol Toxicol. 39:e701892025.
View Article : Google Scholar : PubMed/NCBI
|
